To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Prostate Cancer: Screening
Tuesday 10th November 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether prostate cancer screening will be eligible for PDEL classification at the Spending Review 2027.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Government is committed to addressing problems before they escalate, to improving people’s lives, and to delivering better long‑term value for taxpayers. To support this approach, the Government will introduce a new category of ringfenced spending at the Spending Review in 2027, the Preventative Departmental Expenditure Limit (PDEL). The PDEL will help facilitate shared resource and accountability across budget holders and will help protect programmes that generate benefits over the longer term. The Government will set out further details in due course.


Written Question
Prostate Cancer: Screening
Monday 9th November 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discount rate the NSC's cost-effectiveness modelling used for the March 2026 recommendation on prostate cancer screening.

Answered by Diana Johnson - Minister of State (Department of Health and Social Care)

I refer the Hon Member to the UK National Screening Committee’s published cost effectiveness model, which is available at the following link:

https://view-health-screening-recommendations.service.gov.uk/prostate-cancer/


Written Question
Prostate Cancer: Screening
Thursday 10th September 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what impact assessment was made of the decision to withdraw the Prostate Cancer Risk Management Programme guidance; and whether his Department considered the findings of the Cochrane review entitled Prostate-specific antigen (PSA) test for prostate cancer screening by Franco et al, published on 15 May 2026.

Answered by Diana Johnson - Minister of State (Department of Health and Social Care)

Despite some recent misinformed media coverage, I can confirm to the Hon. Members that there has been no change to the policy in respect of prostate specific antigen (PSA) testing for men aged over 50 years old. Any such man who is concerned about prostate cancer, regardless of whether they have symptoms, remains free to make an appointment with their general practitioner, raise their concerns, and ask for a PSA test, exactly as they have done in the past. No impact assessment was therefore made when the guidance in this area was consolidated and updated in June, as there was no change in policy to assess.

The two main studies from the Cochrane review were included in the UK National Screening Committee modelling when they made their most recent recommendation regarding prostate cancer screening, and it should be noted that the Cochrane review came to the same statistical conclusions as the UK National Screening Committee regarding ‘mortality reduction", sometimes called lives saved, from PSA testing and subsequent treatment.

With regard to the next review of prostate cancer screening, I refer the Hon. Members to the article published by the UK National Screening Committee on 11 August 2026, which is available at the following link:

https://nationalscreening.blog.gov.uk/2026/08/11/the-uk-nscs-prostate-cancer-screening-model-will-remain-open-and-under-review/


Written Question
Prostate Cancer: Screening
Thursday 10th September 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential implications for its policies of the findings of the Cochrane review entitled Prostate-specific antigen (PSA) test for prostate cancer screening by Franco et al, published on 15 May 2026.

Answered by Diana Johnson - Minister of State (Department of Health and Social Care)

Despite some recent misinformed media coverage, I can confirm to the Hon. Members that there has been no change to the policy in respect of prostate specific antigen (PSA) testing for men aged over 50 years old. Any such man who is concerned about prostate cancer, regardless of whether they have symptoms, remains free to make an appointment with their general practitioner, raise their concerns, and ask for a PSA test, exactly as they have done in the past. No impact assessment was therefore made when the guidance in this area was consolidated and updated in June, as there was no change in policy to assess.

The two main studies from the Cochrane review were included in the UK National Screening Committee modelling when they made their most recent recommendation regarding prostate cancer screening, and it should be noted that the Cochrane review came to the same statistical conclusions as the UK National Screening Committee regarding ‘mortality reduction", sometimes called lives saved, from PSA testing and subsequent treatment.

With regard to the next review of prostate cancer screening, I refer the Hon. Members to the article published by the UK National Screening Committee on 11 August 2026, which is available at the following link:

https://nationalscreening.blog.gov.uk/2026/08/11/the-uk-nscs-prostate-cancer-screening-model-will-remain-open-and-under-review/


Written Question
Prostate Cancer: Screening
Thursday 10th September 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the UK National Screening Committee will next review its recommendation on prostate cancer screening.

Answered by Diana Johnson - Minister of State (Department of Health and Social Care)

Despite some recent misinformed media coverage, I can confirm to the Hon. Members that there has been no change to the policy in respect of prostate specific antigen (PSA) testing for men aged over 50 years old. Any such man who is concerned about prostate cancer, regardless of whether they have symptoms, remains free to make an appointment with their general practitioner, raise their concerns, and ask for a PSA test, exactly as they have done in the past. No impact assessment was therefore made when the guidance in this area was consolidated and updated in June, as there was no change in policy to assess.

The two main studies from the Cochrane review were included in the UK National Screening Committee modelling when they made their most recent recommendation regarding prostate cancer screening, and it should be noted that the Cochrane review came to the same statistical conclusions as the UK National Screening Committee regarding ‘mortality reduction", sometimes called lives saved, from PSA testing and subsequent treatment.

With regard to the next review of prostate cancer screening, I refer the Hon. Members to the article published by the UK National Screening Committee on 11 August 2026, which is available at the following link:

https://nationalscreening.blog.gov.uk/2026/08/11/the-uk-nscs-prostate-cancer-screening-model-will-remain-open-and-under-review/


Written Question
Autism: Children
Tuesday 19th May 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the waiting time for children to access an autism spectrum disorder assessment.

Answered by Preet Kaur Gill

NHS England publishes quarterly Autism Waiting Time Statistics, which are available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/autism-statistics

These set out the waiting times for children to access an autism spectrum disorder assessment for each integrated care board (ICB) in England. These are statistics in development and do not yet represent a complete picture of waiting times for autism assessments in England. Work to determine which provider organisations should be submitting data for autistic people is ongoing.

The Government has recognised that, nationally, demand for assessments for autism has grown significantly in recent years and that people of all ages are experiencing severe delays for accessing such assessments. The Government’s 10-Year Health Plan will make the National Health Service fit for the future, and reforms to the Special Educational Needs and Disabilities focus on improving early intervention and support.

ICBs are responsible for planning and commissioning services to meet the needs of their local populations, including making decisions about how best to manage demand and capacity within available resources. The Medium-Term Planning Framework, published 24 October 2025, was explicit that ICBs and providers are expected to optimise existing resources to reduce long waits for autism assessments and improve the quality of assessments by implementing existing and new guidance, as published.

In April 2023, NHS England published a national framework and operational guidance for autism assessment services, which can be found at the following link:

https://www.england.nhs.uk/publication/autism-diagnosis-and-operational-guidance/

This guidance intends to help the NHS improve autism assessment services and improve the experience for those referred to a service.

In December 2025, we launched an independent review into the Prevalence and Support for mental health conditions, attention deficit hyperactivity disorder, and autism. The review’s interim report, published at the end of March, sets out the evidence reviewed so far on prevalence, describes the impact of rising demand for diagnosis and support, identifies where the evidence is uncertain, and outlines the key questions for the next phase. It does not offer final conclusions or recommendations. The final report, due in the summer, will make recommendations on how the Government, the health system, and wider public services can respond to increasing demand for support more fairly and effectively so that people receive the right support, at the right time, in the right place.


Written Question
Autism: Children
Tuesday 19th May 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what is the average waiting time for children to access an autism spectrum disorder assessment in each ICB area.

Answered by Preet Kaur Gill

NHS England publishes quarterly Autism Waiting Time Statistics, which are available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/autism-statistics

These set out the waiting times for children to access an autism spectrum disorder assessment for each integrated care board (ICB) in England. These are statistics in development and do not yet represent a complete picture of waiting times for autism assessments in England. Work to determine which provider organisations should be submitting data for autistic people is ongoing.

The Government has recognised that, nationally, demand for assessments for autism has grown significantly in recent years and that people of all ages are experiencing severe delays for accessing such assessments. The Government’s 10-Year Health Plan will make the National Health Service fit for the future, and reforms to the Special Educational Needs and Disabilities focus on improving early intervention and support.

ICBs are responsible for planning and commissioning services to meet the needs of their local populations, including making decisions about how best to manage demand and capacity within available resources. The Medium-Term Planning Framework, published 24 October 2025, was explicit that ICBs and providers are expected to optimise existing resources to reduce long waits for autism assessments and improve the quality of assessments by implementing existing and new guidance, as published.

In April 2023, NHS England published a national framework and operational guidance for autism assessment services, which can be found at the following link:

https://www.england.nhs.uk/publication/autism-diagnosis-and-operational-guidance/

This guidance intends to help the NHS improve autism assessment services and improve the experience for those referred to a service.

In December 2025, we launched an independent review into the Prevalence and Support for mental health conditions, attention deficit hyperactivity disorder, and autism. The review’s interim report, published at the end of March, sets out the evidence reviewed so far on prevalence, describes the impact of rising demand for diagnosis and support, identifies where the evidence is uncertain, and outlines the key questions for the next phase. It does not offer final conclusions or recommendations. The final report, due in the summer, will make recommendations on how the Government, the health system, and wider public services can respond to increasing demand for support more fairly and effectively so that people receive the right support, at the right time, in the right place.


Written Question
NHS: Staff
Wednesday 29th April 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how he plans to enforce new minimum NHS staff standards, and measure them at ward level.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The NHS Staff Standards will be mandatory. Trust performance against them will be measured via the NHS National Oversight Framework.


Written Question
Nurses
Wednesday 29th April 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if the Government will introduce a statutory duty in England to calculate and take reasonable steps to maintain safe nurse staffing on adult acute wards, with ward-level public reporting and mandatory escalation when recognised staffing risk indicators are breached.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

It has not proved possible to respond to the hon. Member in the time available before Prorogation.


Written Question
Fampridine
Wednesday 18th March 2026

Asked by: Toby Perkins (Labour - Chesterfield)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions he has had with the National Institute for Health and Care Excellence on access to fampridine for people with multiple sclerosis in England.

Answered by Zubir Ahmed

Health is a devolved matter and decisions on the availability of medicines in the devolved administrations are a matter for their own governments.

Ministers and Department officials have had no recent discussions with the National Institute for Health and Care Excellence (NICE) about access to fampridine. NICE’s updated guideline on the diagnosis and management of multiple sclerosis (MS) in adults, published in June 2022, recommends that fampridine should not be offered to treat mobility issues in people with MS as it is not found to be a cost-effective treatment at the current list price. NICE keeps its guidance under active surveillance and decisions on whether published guidelines should be updated in light of new evidence are taken by the NICE prioritisation board, chaired by the NICE Chief Medical Officer, in line with its published prioritisation framework. NICE has indicated that it has no current plans to review its recommendations on fampridine.